Partnership announced as AMPLY appoints Dr Oliver Rausch as Chief Scientific Officer
AMPLY Discovery Limited (“AMPLY”), a UK-based AI-driven drug discovery company, has today announced a strategic investment from Keeps Biomed, a subsidiary of South Korean specialist biotech company Keeps Biopharma. The investment is accompanied by an agreement between the companies to explore future collaboration opportunities in oncology.
AMPLY also announced the appointment of Dr Oliver Rausch as Chief Scientific Officer (CSO). Dr Rausch joins from Storm Therapeutics, bringing deep expertise in RNA biology and oncology drug discovery to accelerate target validation, portfolio progression and partner readiness.
AMPLY’s platform applies AI to mine multi-omic datasets and uncover disease-relevant signals - including non-coding genomic regions - and then validates findings through iterative laboratory testing, enabling the rapid prioritisation of high-quality therapeutic programmes for partnering.
Dr Ben Thomas, CEO of AMPLY Discovery, said: “This strategic investment is an important endorsement of AMPLY’s platform and our approach to oncology. We’re building a company designed for partnering - generating high-quality, data-driven programmes and taking them to clear inflection points. We’re delighted to welcome Keeps Biomed as a strategic investor, and to bring Oliver on board as CSO to help sharpen our oncology execution and partnering readiness.”
Ha Young Kim, CEO of Keeps Biopharma, said: “We see significant opportunity in applying advanced AI-enabled discovery approaches to build a differentiated oncology pipeline. AMPLY’s platform and team align strongly with our strategic direction, and we look forward to developing collaboration opportunities in oncology.”
Dr Oliver Rausch, CSO of AMPLY Discovery, added: “AMPLY’s platform integrates cutting-edge biological insights and experimental validation - exactly what’s needed to translate computational discovery into credible therapeutic programmes. I’m excited to join the team and help drive oncology programmes towards the kind of robust datasets and development plans that partners and investors expect.”
AMPLY was spun out of Queen’s University Belfast and operates a portfolio model that generates multiple discovery programmes in therapeutic areas of high unmet need, with a focus on producing licensable assets and partnering opportunities at defined value-creation milestones.
Sync NI's Autumn 2025 magazine explores how Northern Ireland is moving AI from pilot to production
This issue features exclusive insights from industry leaders on real-world AI implementation, responsible adoption, enterprise infrastructure, and how data-driven innovation is transforming businesses across the region.
Read the Big Data Special Edition free online →
Stay connected with NI's tech community:
Subscribe to our newsletter – Get the latest tech news, job opportunities, and events delivered to your inbox
Visit Sync NI – Your daily source for Northern Ireland technology news
